Diagnostic significance of placental growth factor in women with unspecified preeclampsia

Introduction. Up to 10% of pregnant women suffer from hypertensive disorders, but preeclampsia (PE) occupies a special place, complicating approximately 2–8% of gestations worldwide.
Aim. The pathogenesis of PE is not fully understood, but there is no doubt that it is closely related to angiogenic imbalance. Materials and methods. The study included 72 patients admitted to an obstetric hospital with suspected PE. Depending on the value of PLGF, the participants were divided into 3 groups: patients with a high risk of placental dysfunction (n = 37) (<12 pg/ ml), patients with a medium risk of placental dysfunction (n = 21) (12–100 pg/ml), and patients with a low risk of placental dysfunction (n = 14) (>100 pg/ml).
Results. In patients with a high risk of placental dysfunction, severe PE was statistically significantly more common, as was the shortest interval before premature delivery, as well as adverse maternal and neonatal outcomes. Based on the level of PLGF and proteinuria, a prognostic model was developed to determine the likelihood of developing severe PE, with a specificity and sensitivity of 94.0% and 81.8%, respectively.
Conclusions. The introduction of PLGF analysis into clinical practice can help predict severe PE, simplify risk stratification, and implement personalized treatment strategies and dynamic monitoring, which can improve maternal and perinatal outcomes.

1. Cresswell JA, Alexander M, Chong MYC, Link HM, Pejchinovska M, Gazeley U et al. Global and regional causes of maternal deaths 2009–20: a WHO systematic analysis. Lancet Global Health. 2025;13(4):e626–e634. https://doi.org/10.1016/S2214-109X(24)00560-6.

2. La Cour EE, Malange VNE, Mohaissen T, Christiansen M, Brok JS, Gade C et al. Causes of Neonatal Mortality in the European Region: A WHO-based analysis and Systematic Review. Eur J Pediatr. 2025;184(10):628. https://doi.org/10.1007/s00431-025-06467-0.

3. Burwick RM, Rodriguez MH. Angiogenic Biomarkers in Preeclampsia. Obstet Gynecol. 2024;143(4):515–523. https://doi.org/10.1097/AOG.0000000000005532.

4. Rana S, Burke SD, Karumanchi SA. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022;226(2):S1019–S1034. https://doi.org/10.1016/j.ajog.2020.10.022.

5. Khodzhaeva ZS, Muminova KT, Poluektova AA, Avdeeva AM, Tokareva AO, Kukaev EN et al. Changes in placental growth factor levels in patients with different pregnancy complications. Akusherstvo i Ginekologiya (Russian Federation). 2025;(5):86–96. (In Russ.) https://doi.org/10.18565/aig.2025.95.

6. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D et al. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of preeclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023;61(2):168–180. https://doi.org/10.1002/uog.26032.

7. Teka H, Yemane A, Abraha HE, Berhe E, Tadesse H, Gebru F et al. Clinical presentation, maternal-fetal, and neonatal outcomes of early-onset versus late onset preeclampsia-eclampsia syndrome in a teaching hospital in a lowresource setting: A retrospective cohort study. PLoS ONE. 2023;18(2):e0281952. https://doi.org/10.1371/journal.pone.0281952.

8. Savelyeva GM, Shalina RI, Konoplyannikov AG, Simukhina MA. Preeclampsia and eclampsia: New approaches in diagnosis and evaluation of severity. Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2018;6(4):25–30. (In Russ.) https://doi.org/10.24411/2303-9698-2018-14002.

9. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021;398(10297):341–354. https://doi.org/10.1016/S0140-6736(20)32335-7.

10. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–169. https://doi.org/10.1016/j.preghy.2021.09.008.

11. Ходжаева ЗС, Шмаков РГ, Кан НЕ, Баранов ИИ, Горина КА, Долгушина НВ и др. Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. 2024; 53 с. Режим доступа: https://disuria.ru/_ld/15/1564_kr24O10O16MZ.pdf.

12. Li Y, Cagino K, Yee J, Andy C, Borova D, Shah A et al. Short-term preeclampsia prediction: cutoff variations for sFlt-1/PlGF in U.S. Patients with or without hypertensive disorders. Ann Med. 2025;57(1):2591850. https://doi.org/10.1080/07853890.2025.2591850.

13. Pan X, Peng J, Chen Y, Di X, Li P, Zhang G et al. sFlt-1/PlGF ratio thresholds for diagnosing preeclampsia in pregnant women with high blood pressure. Ultrasound Obstet Gynecol. 2025;66(5):631–640. https://doi.org/10.1002/uog.70075.

14. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on preeclampsia: A pragmatic guide for first-trimester screening and prevention. Intl J Gynecol Obstet. 2019;145(S1):1–33. https://doi.org/10.1002/ijgo.12802.

15. Harris K, Xu L, Woodward M, De Kat A, Zhou X, Shang J et al. Early pregnancy maternal blood pressure and risk of preeclampsia: Does the association differ by parity? Evidence from 14,086 women across 7 countries. Pregnancy Hypertens. 2024;37:101136. https://doi.org/10.1016/j.preghy.2024.101136.

16. Norman SJ, Fontus G, Forestier C, Hiba T, Colon Pagan S, Osondu M et al. The Protective Effect of Abortion on Preeclampsia: An Analysis of Current Research. Cureus. 2024;16(2):e54131. https://doi.org/10.7759/cureus.54131.

17. Mohamedain A, Rayis DA, AlHabardi N, Adam I. Association between previous spontaneous abortion and preeclampsia: a case – control study. BMC Pregnancy Childbirth. 2022;22(1):715. https://doi.org/10.1186/s12884-022-05053-8.

18. Kuz’menko GN, Panova IA, Klycheva MM, Ageev AA, Nazarov SB. Metabolic changes of platelets in pregnant women with hypertensive disorders according to platelet lysate indices. Russian Bulletin of Obstetrician-Gynecologist. 2024;24(4):5–12. (In Russ.) https://doi.org/10.17116/rosakush2024240415.

19. Zhou Y, Xiao C, Yang Y. Pre-pregnancy body mass index combined with peripheral blood PLGF, DCN, LDH, and UA in a risk prediction model for pre-eclampsia. Front Endocrinol. 2024;14:1297731. https://doi.org/10.3389/fendo.2023.1297731.

20. Pylaeva NYu, Shifman EM, Kulikov AV, Pylaev AV. Association Between Predelivery Proteinuria and Pregnancy and Delivery Outcome in Patients with Preeclampsia. Doktor.Ru. 2021;20(6):26–32. (In Russ.) https://doi.org/10.31550/1727-2378-2021-20-6-26-32.

21. Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM et al. Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes. Obstet Gynecol. 2020;135(3):665–673. https://doi.org/10.1097/AOG.0000000000003694.

22. Duhig KE, Myers JE, Gale C, Girling JC, Harding K, Sharp A et al. Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial. Pregnancy Hypertens. 2021;23:41–47. https://doi.org/10.1016/j.preghy.2020.10.005.

23. Zhang L, Li W, Chi X, Sun Q, Li Y, Xing W et al. Predictive performance of sFlt-1, PlGF and the sFlt-1/PlGF ratio for preeclampsia: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025;54(4):102925. https://doi.org/10.1016/j.jogoh.2025.102925.